Ozospas Tablet contains Drotaverine hydrochloride 80 mg, a potent antispasmodic agent primarily used to relieve smooth muscle spasms in various clinical conditions. Drotaverine acts by selectively inhibiting phosphodiesterase-IV, leading to increased intracellular cyclic AMP levels and subsequent relaxation of smooth muscle tissue without affecting normal muscle tone. This mechanism makes Ozospas effective in alleviating spasmodic pain associated with gastrointestinal, biliary, renal, and genitourinary tract disorders, including irritable bowel syndrome, biliary colic, renal colic, and dysmenorrhea. Additionally, it is utilized to facilitate diagnostic and therapeutic procedures by reducing smooth muscle spasms. Ozospas is generally well-tolerated, with a favorable safety profile; common adverse effects may include mild hypotension, dizziness, or headache. It is contraindicated in patients with known hypersensitivity to drotaverine or related compounds, severe hypotension, or cardiac arrhythmias. Dosage should be individualized based on the severity of symptoms and patient response, typically administered orally one to three times daily. Caution is advised in pregnant or lactating women and patients with underlying cardiovascular conditions. Ozospas Tablet offers effective symptomatic relief by targeting smooth muscle spasms, improving patient comfort and quality of life in various spastic disorders.